You are viewing the site in preview mode

Skip to main content

Table 1 Baseline clinical and laboratorial characteristics of HD patients

From: Safely reducing haemodialysis frequency during the COVID-19 pandemic

  Twice weekly HD (n = 166) Thrice weekly HD (n = 236) P value
Age (years) 65.0 [54.8–74.3] 59.0 [49.0–71.0] < 0.001
Sex– Male (%) 107 (64.5) 154 (65.3) 0.870
Ethnicity - White British (%) 110 (66.3) 167 (70.8) 0.339
Pre HD weight (Kg)a 73.5 [62.0–85.3] 76.2 [64.2–91.4] 0.038
BMIb 25.8 [22.9–29.4] 27.5 [23.3–31.6] 0.050
Last URR (%)c 71.1 [65.4–75.5] 69.3 [63.1–74.4] 0.009
Corrected Calciumd (mmol/L) 2.36 ± 0.18 2.34 ± 0.17 0.283
Phosphatee (mmol/L) 1.56 [1.27–1.89] 1.68 [1.33–2.07] 0.023
Parathyroid Hormonef (pmol/L) 26.9 [12.5–56.8] 28.9 [13.2–51.9] 0.361
Haemoglobing (g/L) 107 ± 16.1 107 ± 17.6 0.873
Potassiumh (mmol/L) 4.50 [4.00–5.20] 4.90 [3.20–5.50] < 0.001
Albumini (g/L) 38.0 [34.1–41.0] 38.5 [35.0–41.0] 0.358
Pre-HD average SBPj 148 ± 21.7 147 ± 22.4 0.617
Pre-HD average DBPk 74.0 [62.3–84.8] 77.5 [67.0–88.0] 0.082
Post-HD average SBPl 139 [126–154] 137 [121–156] 0.980
Post-HD average DBPm 72.0 [63.0–80.0] 71.5 [63.8–83.3] 0.584
Average UFn (L) 1.40 [1.00–2.00] 2.00 [1.50–2.70] < 0.001
Anuric Statuso (n) 16 N/A  
Dialysis Vintage (months) 21 (6.3–14.5) 29.5 (11.9–261) 0.013
Primary Renal Disease
 Diabetic Nephropathy (%) 51 (30.7) 81 (34.3) 0.450
 Hypertensive/Renovascular disease (%) 27 (16.3) 30 (12.7) 0.314
 Glomerulonephritis (%) 21 (12.7) 31 (13.1) 0.886
 ADPKD (%) 15 (9.0) 13 (5.5) 0.172
 Urological (%) 13 (7.8) 24 (10.2) 0.425
 Pyelonephritis (%) 3 (1.8) 11 (4.7) 0.125
 ANCA-associated vasculitis (%) 4 (2.4) 5 (2.1) 0.847
 Other (%) 17 (10.2) 16 (6.8) 0.214
 Unknown (%) 15 (9.0) 25 (10.6) 0.610
Comorbidity
 Ischaemic heart disease (%) 25 (15.1) 40 (17.0) 0.613
 Heart Failure (%) 5 (3.0) 18 (7.6) 0.049
 CVA (%) 16 (9.7) 35 (14.8) 0.124
 Diabetes Mellitus (%) 62 (37.4) 101 (42.8) 0.274
 ACEi (%) 30 (18.1) 46 (19.5) 0.721
 ARB (%) 19 (11.5) 32 (13.6) 0.532
  1. Results are expressed as mean ± SD, median [IQR; interquartile range] or n (%).p-value calculated using unpaired T test for parametric data and Mann-Whitney U Test for non-parametric data. Categorical variables were analysed by Chi-square test. Abbreviations: BMI – Body Mass Index, HD – Haemodialysis, SBP – Systolic Blood Pressure, DBP – Diastolic Blood Pressure, URR – Urea Reduction Ratio, ADPKD – Autosomal Dominant Polycystic Kidney Disease, CVA – Cerebrovascular event, ACEi– Angiotensin converting enzyme inhibitor, ARB - Angiotensin receptor blocker. amissing for 2 patients in twice weekly group. bmissing for 2 patients in twice weekly group and 4 patients in thrice weekly group. cmissing for 26 patients in twice weekly group and 38 patients in thrice weekly group. dmissing for 2 patients in twice weekly group. emissing for 2 patients in twice weekly group. fmissing for 4 patients in twice weekly group and 78 patients in thrice weekly group. gmissing for 2 patients in twice weekly group. hmissing for 2 patients in twice weekly group. imissing for 1 patient in twice weekly group. jPre-HD average SBP data missing for 4 patients in twice weekly group and 4 patients in 3x week HD group. kmissing for 4 patients in twice weekly group and 4 patients in thrice weekly group. lmissing for 9 patients in twice weekly group and 10 patients in thrice weekly group. mPost-HD average DBP data missing for 9 patients in twice weekly group and 10 patients in thrice weekly group. nmissing for 3 patients in twice weekly group. omissing data 79 patients
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us